Ang JBS Science na nakabase sa Pennsylvania ay nagsabi ngayon na nakatanggap ito ng $ 3 milyon na Bridge Award para sa Small Business Innovation Research IIB mula sa National Cancer Institute. Binuo ng kumpanya ang unang likidong biopsy na produkto, na ang urine DNA screening para sa maagang liver cell cancer (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of kanser sa atay. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating pamamaga DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
Sinabi ng JBS na nakipagtulungan ito kay James Hamilton ng Johns Hopkins University Medical Center at Hie-Won Hann ng Thomas University Hospital upang isulong ang pagbuo ng pagsusuri sa ihi ng kanser sa atay.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
